

Supplementary Table 2. Demographic, clinical and laboratory characteristics of rheumatoid arthritis patients, co-morbidity controls, and healthy controls.

	RA	CC	HC
Patients,n	10	10	10
Age,years	58.5(13.75)	80(17.5)	56(5)
Females,n	8(80%)	6(60%)	8(80%)
Disease duration (RA),years	14.4±11.4	-	-
DAS28*	5.8±1.3	-	-
Patients with DAS28 > 5.1*,n	6(60%)	-	-
CRP,mg/dl	1.89(0.73-5.46)	0.20(0.09-1.50)	0.09(0.09-0.28)
Patients with CRP > 0.5 mg/dl,n	10(100%)	2(20%)	0
IL-6,pg/ml	11.52(0.49-75.75)	0.75(0.47-9.64)	0.49(0.49-1.25)
TNFalpha,pg/ml	1.38(0.61-33.63)	0.70 (0.55-1.01)	0.60 (0.60-3.24)
IL-1,pg/ml	0.18(0.11-5.73)	0.13(0.07-0.15)	0.15(0.08-0.29)

RA: rheumatoid arthritis; CC: co-morbidity controls; HC: healthy controls; DAS28: disease activity score in 28 joints; CRP: C-reactive protein; IL-6: interleukin-6; TNFalpha: Tumor necrosis factor alpha; IL-1beta: interleukin-1beta.

Values are expressed as mean ±standard deviation, or median (range). Age is expressed as median (interquartile range).

*DAS28 <2.6: disease remission; 2.6-3.2: mild active disease; 3.2-5.1: moderate active disease; >5.1: severe active disease [Gaujoux-Viala C, et al. *Joint Bone Spine* 2012;79:149-155].